Potential COVID-19 remedies from repurposed drugs and herbal small RNAs

Yang, Yang1; Huang, Fengming2; Qiao, Xiangyu2; Chen, Sheng3; Zhang, Cong2; Deng, Xingyu2; Gu, Wentao4; Peng, Ling1; Cao, Mengli1; Jiang, Jingmei4; Gao, George F.5; Liu, Yingxia1; Jiang, Chengyu2

2024-06-01

10.1002/iub.2860

IUBMB LIFE   影响因子和分区

1521-6543

1521-6551

To date, SARS-CoV-2 has caused millions of deaths, but the choice of treatment is limited. We previously established a platform for identifying Food and Drug Administration (FDA)-approved repurposed drugs for avian influenza A virus infections that could be used for coronavirus disease 2019 (COVID-19) treatment. In this study, we analyzed blood samples from two cohorts of 63 COVID-19 patients, including 19 patients with severe disease. Among the 39 FDA-approved drugs we identified for COVID-19 therapy in both cohorts, 23 drugs were confirmed by literature mining data, including 14 drugs already under COVID-19 clinical trials and 9 drugs reported for COVID-19 treatments, suggesting the remaining 16 FDA-approved drugs may be candidates for COVID-19 therapy. Additionally, we previously reported that herbal small RNAs (sRNAs) could be effective components in traditional Chinese medicine (TCM) for treating COVID-19. Based on the abundance of sRNAs, we screened the 245 TCMs in the Bencao (herbal) sRNA Atlas that we had previously established, and we found that the top 12 TCMs for COVID-19 treatment was consistent across both cohorts. We validated the efficiency of the top 30 sRNAs from each of the top 3 TCMs for COVID-19 treatment in poly(I:C)-stimulated human non-small cell lung cancer cells (A549 cells). In conclusion, our study recommends potential COVID-19 remedies using FDA-approved repurposed drugs and herbal sRNAs from TCMs.

COVID-19 herbal small RNAs repurposed drugs traditional Chinese medicines

SCI

英语

第一 ; 通讯

State Key Laboratory Special Fund[2060204] ; National Natural Science Foundation of China["32100104","81788101"] ; Overseas Expertise Introduction Project for Discipline Innovation[BP0820029] ; Chinese Academy of Medical Sciences Initiative for Innovative Medicine["2021-I2M-1-022","2022-I2M-CoV19-001"] ; CAMS Endowment Fund[2021-CAMS-JZ001] ; Fundamental Research Funds for Central Universities[2017PT31017]

Biochemistry & Molecular Biology ; Cell Biology

Biochemistry & Molecular Biology ; Cell Biology

WOS:001254303500001

WILEY

BIOLOGY & BIOCHEMISTRY

Web of Science

1.Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Natl Clin Res Ctr Infect Dis,Hosp 2,State Key Disc, Shenzhen Key Lab Pathogen & Immun, Shenzhen, Peoples R China
2.Chinese Acad Med Sci & Peking Union Med Coll, Inst Basic Med Sci, State Key Lab Common Mech Res Major Dis, Beijing, Peoples R China
3.Shenzhen Tradmonal Chinese Med Hosp, Shenzhen, Guangdong, Peoples R China
4.Chinese Acad Med Sci, Sch Basic Med, Dept Epidemiol & Biostat, Peking Union Med Coll,Inst Basic Med Sci, Beijing, Peoples R China
5.Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Beijing, Peoples R China

Yang, Yang,Huang, Fengming,Qiao, Xiangyu,et al. Potential COVID-19 remedies from repurposed drugs and herbal small RNAs[J]. IUBMB LIFE,2024.

Yang, Yang.,Huang, Fengming.,Qiao, Xiangyu.,Chen, Sheng.,Zhang, Cong.,...&Jiang, Chengyu.(2024).Potential COVID-19 remedies from repurposed drugs and herbal small RNAs.IUBMB LIFE.

Yang, Yang,et al."Potential COVID-19 remedies from repurposed drugs and herbal small RNAs".IUBMB LIFE (2024).